Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar;22(3):681-682.
doi: 10.1111/ajt.16923. Epub 2021 Dec 18.

Revisiting acute T cell-mediated rejection in kidney allografts

Ilkka Helanterä  1 , Michael Mengel  2
Affiliations
Free article
Editorial

Revisiting acute T cell-mediated rejection in kidney allografts

Ilkka Helanterä et al. Am J Transplant. 2022 Mar.
Free article
No abstract available

Keywords: clinical research/practice; editorial/personal viewpoint; histocompatibility; immunosuppressant; immunosuppression/immune modulation; kidney transplantation/nephrology; rejection: T cell mediated (TCMR).

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.
    1. Sellarés J, de Freitag DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-399.
    1. Rampersad C, Balshaw R, Gibson I, et al. The negative impact of T-cell mediated rejection on renal allograft survival in the modern era [published online ahead of print October 30, 2021]. Am J Transplant. this issue. doi:10.1111/ajt.16883
    1. Sood P, Cherikh WS, Toll AE, Mehta RB, Hariharan S. Kidney allograft rejection: diagnosis and treatment practices in USA- A UNOS survey. Clin Transplant. 2021;35(4):e14225. doi:10.1111/ctr.14225
    1. Budde K, Prashar R, Haller H, et al. Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial. J Am Soc Nephrol. 2021;ASN.2021050628. doi:10.1681/ASN.2021050628

LinkOut - more resources